Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): British Society for Allergy and Clinical Immunology

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): British Society for Allergy and Clinical Immunology

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): British Society for Allergy and Clinical Immunology
07 March 2013
(44.59 Kb 12 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 01 March 2013